Chinook Therapeutics to Present at SVB Securities Global Biopharma Conference
Chinook Therapeutics, Inc. (Nasdaq: KDNY) announced management's participation in a virtual fireside chat on February 14, 2023, at the SVB Securities Global Biopharma Conference at 11:20 am ET. The event will also include 1x1 meetings. Interested parties can access the live webcast and archived recordings through the Investors section of its website. Chinook focuses on precision medicines for kidney diseases, with key products like atrasentan and BION-1301 currently in clinical trials.
- None.
- None.
SEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 11:20 am ET, as well as 1x1 meetings.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcast will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook’s research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
What event is Chinook Therapeutics participating in on February 14, 2023?
What time does the Chinook Therapeutics fireside chat start?
Where can I watch the Chinook Therapeutics conference presentation?
What are the main products being developed by Chinook Therapeutics?
Is the archived webcast of the Chinook Therapeutics presentation available?
